A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Inclusion Criteria:

• ≥18 years old.

• Locally advanced or metastatic solid tumor with KRAS G12D mutation.

• For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on priorstandard treatment, intolerance to or ineligibility for standard treatment, declinedavailable therapies that are known to confer clinical benefit, or no standardavailable treatment to improve the disease outcome.

• Cohort specific requirements aas defined in the protocol.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

• Prior treatment with any KRAS G12D inhibitor

• Known additional invasive malignancy within 1 year of the first dose of study drug

• History of organ transplant, including allogeneic stem cell transplantation

• Significant, uncontrolled medical condition

• History or presence of an ECG abnormality

• Inadequate organ function

Other protocol-defined Inclusion/Exclusion Criteria may apply